Pfizer (PFE) and Astellas Pharma said long-term follow-up results from a phase 3 clinical trial demonstrated a 30% reduction in the risk of death for men with metastatic hormone-sensitive prostate cancer.
The study, which followed patients for five years, found that treatment with XTANDI plus androgen deprivation therapy improved survival rates compared with placebo plus ADT, the companies said Thursday in a statement.
The data will be presented at the American Society of Clinical Oncology's annual meeting in Chicago on June 3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.